A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China

Chemotherapy

Volumn 56, Issue 6, 2010, Pages 472-477

  Yu, Yong Feng ^a   Chen, Zhi Wei ^a   Zhou, Zhen ^a   Song, Zheng Bo ^a   Li, Zi Ming ^a   Jian, Hong ^a   Zhang, Yi Fei ^a   Lu, Shun ^a  

^a SHANGHAI CHEST HOSPITAL   (China)

Author keywords

Docetaxel; Non small cell lung cancer; Overall survival; Pemetrexed; Progression free survival; Toxicity

Indexed keywords

CISPLATIN; DOCETAXEL; PEMETREXED;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHINA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HEALTH CARE COST; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 78449234025     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321016     Document Type: Article

References (29)

1. Statistical data was extracted from www. moh.gov.cn.
2. Holmes J, Dunlop D, Hemmet L, et al: A costeffectiveness analysis of docetaxel in the second- line treatment of non-small cell lung cancer. Pharmacoeconomics 2004; 22: 581-589.
3. Adjei AA: Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res 2004; 10(suppl):4276s-4280s.
4. Beartz A, Garasino I, Cavina R: Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study. Lung Cancer 2008; 60: 245-250.
5. Shepard FA: Prospective randomised trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
6. Felip E, Rosell R: Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC). Ther Clin Risk Manag 2008; 4: 579-585. (Pubitemid 352037897)
7. Zhang YF, Chen ZW, Lu S: Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer. China Med J 2009; 122: 2472-2476.
8. Horn L, Visval A, Leighl NB: Docetaxel in non-small cell lung cancer: impact on quality of life and pharmacoeconomics. Drugs Aging 2007; 24: 411-428.
9. Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with nonsmall- cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
10. Fossella FV, DeVore R, Kerr RN, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non- Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18: 2354-2362.
11. Wildi JD, Baggstrom MQ, Suresh R, et al: A stage I study of docetaxel and bexarotene. Chemotherapy 2008; 54: 125-130.
12. Cohen MH, Johnson JR, Wang YC, et al: FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist 2005; 10: 363-368.
13. Nagai S, Takenaka K, Sonobe M, et al: Schedule- dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and nonsmall cell lung cancer cell lines. Chemotherapy 2008; 54: 166-175.
14. Smit EF, Burgers SA, Biesma B, et al: Randomized stage II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2009; 27: 2038-2045.
15. Scagliotti GV, Parikh P, von Pawel J, et al: Stage III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced- stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
16. Hanna N, Shepherd FA, Fossella FV, et al: Randomized stage III trial of pemetrexed versus docetaxel in patients with non-smallcell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597.
17. Pujol JL, Paul S, Chouaki N, Peterson P, et al: Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis. J Thorac Oncol 2007; 2: 397-401.
18. Gridelli C, Ardizzoni A, Ciardiello F, et al: Second-line treatment of advanced nonsmall cell lung cancer. J Thorac Oncol 2008; 3: 430-440.
19. Fossella F, Pereira JR, von Pawel J, et al: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21: 3016-3024.
20. Wakelee H, Belani CP: Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist 2005; 10: 1-10.
21. D'Addario G, Pintilie M, Leighl NB, et al: Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005; 23: 2926-2936.
22. Di Maio M, Chiodini P, Georgoulias V, et al: Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced nonsmall- cell lung cancer. J Clin Oncol 2009; 27: 1834-1843.
23. Morabito A, Piccirillo MC, Falasconi F, et al: Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 2009; 14: 378-390.
24. Pakkala S, Ramalingam SS: Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy. Clin Lung Cancer 2009; 10:S17-23.
25. Herbst RS, Sun Y, Eberhardt WE, et al: Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, stage 3 trial. Lancet Oncol 2010; 11: 619-626.
26. Tawfik HA, Taha AEM, Attia GA: Induction docetaxel and cisplatin followed by weekly docetaxel and cisplatin with concurrent radiotherapy in locally advanced stage III non small cell lung cancer (LA-NSCLC): a stage II study. J Egypt Natl Canc Inst 2007; 19: 15-20.
27. Engels FK, Verweij J: Docetaxel administration schedule: from fever to tears? A review of randomised studies. Eur J Cancer 2005; 41: 1117-1126.
28. Chen YM, Shih JF, Perng RP, et al: A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest 2006; 129: 1031-1038.
29. Ko YH, Lee MA, Hong YS, et al: Docetaxel monotherapy as second-line treatment for pretreated advanced non-small cell lung cancer patients. Korean J Intern Med 2007; 22: 178-185.